{"id":23279,"date":"2023-06-01T18:43:10","date_gmt":"2023-06-01T13:13:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23279"},"modified":"2023-06-14T11:03:07","modified_gmt":"2023-06-14T05:33:07","slug":"medtech-news-for-cepheid-anika-emvision","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision","title":{"rendered":"THINK Surgical\u2019s TMINI Miniature Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast\u00ae US Pivotal Phase III Study; EMVision\u2019s Portable Brain Scanner Trial; HeartBeam and Samsung\u2019s Strategic Alliance Agreement; Eosolutions\u2019s Dr. Banner Balloon Guide Catheter"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a01074f24a9a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a01074f24a9a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#TMINI_Miniature_Robotic_System_by_THINK_Surgical_Received_FDA_510k_Clearance\" >TMINI Miniature Robotic System by THINK Surgical Received FDA 510(k) Clearance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#Cepheids_Xpert_NPM1_Mutation_Test_Received_a_CE_Mark\" >Cepheid\u2019s Xpert NPM1 Mutation Test Received a CE Mark&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#Anika_Completed_Enrollment_in_Hyalofast%C2%AE_US_Pivotal_Phase_III_Study\" >Anika Completed Enrollment in Hyalofast\u00ae US Pivotal Phase III Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#EMVision_Initiated_the_Stage_II_of_the_Portable_Brain_Scanner_Trial\" >EMVision Initiated the Stage II of the Portable Brain Scanner Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#HeartBeam_Entered_into_Strategic_Alliance_Agreement_with_Samsung\" >HeartBeam Entered into Strategic Alliance Agreement with Samsung<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\/#Eosolutions_Corp_Announced_the_Full_Commercial_Launch_of_the_Dr_Banner_Balloon_Guide_Catheter\" >Eosolutions Corp. Announced the Full Commercial Launch of the Dr. Banner Balloon Guide Catheter<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-tmini-miniature-robotic-system-by-think-surgical-received-fda-510-k-clearance\"><span class=\"ez-toc-section\" id=\"TMINI_Miniature_Robotic_System_by_THINK_Surgical_Received_FDA_510k_Clearance\"><\/span><strong>TMINI Miniature Robotic System by THINK Surgical Received FDA 510(k) Clearance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 30, 2023, <\/strong>THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TMINI&#x2122; Miniature Robotic System.<\/p>\n\n\n\n<p>A wireless robotic handpiece that is part of the TMINI system helps surgeons perform total knee replacements. The TMINI robotic handpiece automatically corrects the surgeon&#8217;s hand movement to locate bone pins along with precisely defining planes while executing a three-dimensional surgical plan based on a CT scan. TMINI is simple to use and takes the place of many of the current knee replacement surgery tools.<\/p>\n\n\n\n<p>Together with Cambridge, UK-based R&amp;D consultancy Sagentia Innovation, THINK Surgical created the TMINI robotic handpiece. The innovative design of the TMINI robotic handpiece, which is simple for surgeons and staff to incorporate into operating room workflows, was made possible by the combined technical expertise of both companies.&nbsp;<\/p>\n\n\n\n<p>To maintain its commitment to an open implant library, THINK Surgical will gradually add new implant choices to the platform. Given the simplicity of the TMINI system and the open implant strategy, a large customer base that may have previously been wary of robotics should find interest in the product.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;With its small footprint, open implant platform, and intuitive workflow, the TMINI system opens up robotic possibilities for more clinics, operating rooms, and surgeons,&#8221; <\/em>said Stuart Simpson, president, and chief executive officer of THINK Surgical.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The broader market opportunity for the TMINI system makes this an important development in surgical robotics. It&#8217;s been exciting supporting this project from early concept development through transfer to manufacturing, and we look forward to its commercial success,&#8221; <\/em>said Duncan Smith, managing partner of Sagentia Innovation.<\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>Surgical Robotic System Market<\/strong><\/a>\u201d report, the global surgical robotic devices market was valued at <strong>USD 5.02 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>11.50%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 9.64 billion<\/strong> by 2028. The demand for surgical robotic systems is witnessing a surge due to increasing surgical procedures which can be attributed to various factors such as the increasing geriatric population who form a big part of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-epidemiology-forecast\"><strong>at-risk population for prostate cancer<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/endometriosis-market\"><strong>endometriosis<\/strong><\/a>, valvular diseases, among other diseases, growing need for <a href=\"https:\/\/www.delveinsight.com\/blog\/robotics-surgery-transforming-healthcare\"><strong>robot-assisted surgery systems<\/strong><\/a> due to the growing inclination towards minimally invasive surgical approaches, and the innovation in product development which is paving the way for miniaturized surgical robots ultimately contributing in the overall growth of the surgical robotic systems market during the forecast period from 2023-2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cepheid-s-xpert-npm1-mutation-test-received-a-ce-mark\"><span class=\"ez-toc-section\" id=\"Cepheids_Xpert_NPM1_Mutation_Test_Received_a_CE_Mark\"><\/span><strong>Cepheid\u2019s Xpert NPM1 Mutation Test Received a CE Mark&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 30, 2023<\/strong>, US-based molecular diagnostics company Cepheid secured the CE mark for its molecular in vitro diagnostic test, Xpert NPM1 Mutation.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-epidemiology-forecast\"><strong>Acute myeloid leukemia (AML) patients<\/strong><\/a>&#8216; peripheral blood samples are used in the test to measure mutant NPM1 mRNA transcripts (types A, B, and D in exon 12).<\/p>\n\n\n\n<p>The test provides the percentage of mutant NPM1 to ABL1 endogenous control mRNA transcripts using automated real-time reverse transcription polymerase chain reaction.<\/p>\n\n\n\n<p>The European Leukemia Net recommends using quantitative <a href=\"https:\/\/www.delveinsight.com\/report-store\/mllr-and-npm1c-mutant-relapsed-refractory-r-r-acute-leukemia-epidemiology-forecast\"><strong>molecular assessment of NPM1<\/strong><\/a> through qPCR as part of <a href=\"https:\/\/www.delveinsight.com\/report-store\/minimal-residual-disease-market\"><strong>minimal residual disease monitoring<\/strong><\/a> for AML patients with NPM1 mutations.&nbsp;<\/p>\n\n\n\n<p>The company&#8217;s hematology-oncology portfolio, which already includes Xpert BCR-ABL Ultra p190 and Xpert BCR-ABL Ultra, is said to benefit from the addition of the new diagnostic test.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Cepheid oncology medical and scientific Affairs Vice-President Dr. Michael Bates said, <em>\u201cNPM1 mutations are found in approximately one-third of acute myeloid leukemia cases and can be used to monitor response to therapy as well as to predict relapse.<\/em> <em>The Xpert NPM1 Mutation test quantifies the mRNA transcripts of the A, B, and D mutations accounting for approximately 90% of NPM1 mutant cases, plus the ABL control gene, and provides an easy and convenient method of assessing response to therapy and improving the management of patients with AML.\u201d&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/in-vitro-diagnostics-market\"><strong>In-vitro Diagnostics Market<\/strong><\/a>\u201d report, the global in-vitro diagnostics market was valued at <strong>USD 71.01 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>4.71%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 93.60<\/strong> billion by 2028. The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as the rising prevalence of various infectious diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-competitive-landscape\"><strong>COVID-19<\/strong><\/a>, the growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities concerning in-vitro diagnostics among others.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-anika-completed-enrollment-in-hyalofast-us-pivotal-phase-iii-study\"><span class=\"ez-toc-section\" id=\"Anika_Completed_Enrollment_in_Hyalofast%C2%AE_US_Pivotal_Phase_III_Study\"><\/span><strong>Anika Completed Enrollment in Hyalofast\u00ae US Pivotal Phase III Study<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 30, 2023<\/strong>, Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, announced the completion of the enrolment of participants for its pivotal Phase III clinical study of Hyalofast, on its path to achieving FDA approval in the United States.<\/p>\n\n\n\n<p>Hyalofast is a highly differentiating, one-stage, hyaluronic acid (HA), matrix that preserves bone. Hyalofast is implanted in one surgery after debridement of the diseased tissue, as opposed to the current standard of care which requires two surgeries including removal of autologous cartilage, cell expansion, and subsequent cell reimplantation at the diseased site, or an alternative product that requires removing healthy bone to accommodate an implant.&nbsp;<\/p>\n\n\n\n<p>Hyalofast is stocked at the surgical facility and can be easily taken off the shelf during surgery when a cartilage lesion is identified, which lessens the burden on patients and the healthcare system.<\/p>\n\n\n\n<p>Hyalofast is a truly revolutionary treatment for patients with pain and reduced function brought on by cartilage lesions. It is already available in more than 35 countries outside of the United States. The requirement for surgeons to perform and patients to endure a second surgical procedure to use the product currently on the market has restricted the US cartilage repair market. Without the need for a second expensive, invasive surgery, Hyalofast&#8217;s off-the-shelf, bone-preserving design enables surgeons to quickly repair lesions intraoperatively.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis is an important milestone for Anika, bringing us one step closer to making Hyalofast available for patients in the United States,\u201d <\/em>said Anika\u2019s President and CEO, Cheryl R. Blanchard, Ph.D.<em> \u201cThe knee cartilage repair market in the U.S. is large and growing and is perfectly aligned with our strategic focus as we continue to introduce ground-breaking regenerative solutions that expand our Joint Preservation and Restoration portfolio. We believe that Hyalofast will drive significant market expansion and further accelerate our company\u2019s growth in the coming years. We are pleased that FDA has granted Hyalofast Breakthrough Device Designation and has agreed to a modular PMA filing, both of which will facilitate an efficient review process.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/knee-reconstruction-devices-market\"><strong>Knee Reconstruction Devices Market<\/strong><\/a>\u201d report<strong>,<\/strong> the global knee reconstruction devices market was valued at <strong>USD 7.87 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>4.52%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 10.27 billion<\/strong> by 2028. The rise in the demand for knee reconstruction\/replacement devices is predominantly attributed to the burgeoning old-age population and the rising prevalence of various knee-associated musculoskeletal disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoarthritis-market\"><strong>osteoarthritis<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/rheumatoid-arthritis-ra-market\"><strong>rheumatoid arthritis<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\"><strong>psoriatic arthritis<\/strong><\/a>, and others. Also, the growing demand for minimally invasive surgeries and various technological advancements to improve the efficiency of the products are key market drivers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-emvision-initiated-the-stage-ii-of-the-portable-brain-scanner-trial\"><span class=\"ez-toc-section\" id=\"EMVision_Initiated_the_Stage_II_of_the_Portable_Brain_Scanner_Trial\"><\/span><strong>EMVision Initiated the Stage II of the Portable Brain Scanner Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>May 30, 2023,<\/strong> the Australia-based EMVision Medical Devices initiated the Stage II of its clinical trial for its first-generation portable brain scanner.<\/p>\n\n\n\n<p>The first phase of the trial has just recently been completed, involving 30 healthy volunteers.<\/p>\n\n\n\n<p>Further, 150 patients with acute strokes and stroke mimics are expected to enroll in the second stage. Major comprehensive stroke centers in Australia, including Royal Melbourne Hospital, Princess Alexandra Hospital, and Liverpool Hospital, are participating in the trial.<\/p>\n\n\n\n<p>Each site has a population of stroke patients and a committed research team to support a quick patient enrolment process.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>EMVision Medical Devices CEO Dr. Ron Weinberger said, <em>\u201cSignificant preparation and positive collaboration between the EMVision team and hospital staff has been underway to ensure the next phase of our multi-site clinical trials is set up for success.<\/em> <em>We have taken the technical and usability information from Stage I and refined our device for Stage II and although the modifications are not major, they will result in significant performance improvements.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neurology-devices-market\"><strong>Neurology Devices Market<\/strong><\/a>\u201d report,<strong> <\/strong>the global neurology devices market is estimated to grow at a <strong>CAGR<\/strong> of <strong>7.46%<\/strong> during the forecast period from 2023 to 2028. The neurology devices market is observing optimistic market growth due to factors such as the rise in the number of regulatory approvals for neurology devices across the globe. Further, the increasing cases of head injuries owing to accidents, workplace injuries, and others, and the rise in the geriatric population coupled with the increasing prevalence of neurological diseases are going to increase the demand for various neurological devices across the globe. Additionally, the growing focus on improving the safety, affordability, and usability of neurology devices for end users is further expected to result in appreciable revenue growth in the neurology devices market during the forecast period (2023-2028).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-heartbeam-entered-into-strategic-alliance-agreement-with-samsung\"><span class=\"ez-toc-section\" id=\"HeartBeam_Entered_into_Strategic_Alliance_Agreement_with_Samsung\"><\/span><strong>HeartBeam Entered into Strategic Alliance Agreement with Samsung<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 30, 2023, <\/strong>HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung.<\/p>\n\n\n\n<p>Under the terms of the contract, HeartBeam and Samsung will identify and specify opportunities for cooperation, drawing on the knowledge and patented technology of the HeartBeam team in the evaluation and monitoring of cardiac symptoms.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe goal of this partnership is to bring the standard of care for cardiac diagnostic capabilities to patients by utilizing cutting-edge technologies of both Samsung and HeartBeam,\u201d<\/em> said Branislav Vajdic, Ph.D., HeartBeam CEO, and Founder. Branislay further added, <em>\u201cOur newly acquired state-of-the-art, FDA-cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo&#x2122; telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Kevin Jones, Senior Director, Federal Healthcare, Samsung Electronics America, added,<em> \u201cThe strategic collaboration between Samsung and LIVMOR was very successful, resulting in an FDA-cleared solution for Atrial Fibrillation detection centered around the Samsung Galaxy watch and tablet running Samsung&#8217;s defense-grade cyber-security system, Knox. We are excited that LIVMOR is now part of HeartBeam and look forward to continuing our successful collaboration. The potential of combining LIVMOR\u2019s technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiac-monitoring-devices-market\"><strong>Cardiac Monitoring Devices Market<\/strong><\/a>\u201d report, the global cardiac monitoring devices market is estimated at a <strong>CAGR<\/strong> of <strong>5.4%<\/strong> during the forecast period from 2023 to 2028. The demand for cardiac monitoring devices is primarily being boosted by the <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-disease-landscape\"><strong>rising prevalence of cardiovascular diseases<\/strong><\/a>, technological advancement in product development, increasing geriatric population, sedentary lifestyle, and increasing awareness programs regarding cardiovascular diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eosolutions-corp-announced-the-full-commercial-launch-of-the-dr-banner-balloon-guide-catheter\"><span class=\"ez-toc-section\" id=\"Eosolutions_Corp_Announced_the_Full_Commercial_Launch_of_the_Dr_Banner_Balloon_Guide_Catheter\"><\/span><strong>Eosolutions Corp. Announced the Full Commercial Launch of the Dr. Banner Balloon Guide Catheter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>May 24, 2023<\/strong>, EOSolutions Corp., a pioneering medical technology company focused on delivering high-quality catheter solutions, launched Dr. Banner, Balloon Guide Catheter (BGC).&nbsp;<\/p>\n\n\n\n<p>It was developed in collaboration with InNeuroCo, a leading design, consulting, and contract manufacturing group with Dr. Banner setting new benchmarks in catheter technology, providing physicians with unparalleled capabilities.&nbsp;<\/p>\n\n\n\n<p>The device offers various features such as the largest inner diameter (ID) of 0.091, improved proximal stability, distal trackability, and a super-compliant polyurethane balloon.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Dr. Banner marks a significant milestone in the field of neurovascular interventions,&#8221; <\/em>said Anthony Parise, General Manager and Head of Sales &amp; Marketing at EOSolutions Corp. Dr. Banner further added,<em> &#8220;With its unparalleled inner diameter, proximal stability, distal trackability, and super compliant polyurethane balloon, Dr. Banner empowers physicians to overcome the challenges of complex anatomies, providing precise and effective treatment options for their patients. We are excited to respond to the needs of our physicians by introducing this ground-breaking catheter that will improve upon their ability to perform the most challenging neurovascular procedures.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/balloon-catheters-market\"><strong>Balloon Catheters Market<\/strong><\/a>\u201d report,<strong> <\/strong>the global balloon catheters market was valued at <strong>USD 4.60 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>8.78%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 7.62 billion<\/strong> by 2028. Factors such as the rising prevalence of lifestyle disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-epidemiology-forecast\"><strong>hypertension<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><strong>obesity<\/strong><\/a> which present themselves as major risk factors for the development of cardiovascular diseases as well as <a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-aneurysm-stents-market\"><strong>brain aneurysms<\/strong><\/a>, increasing incidence of cancers in the pelvic region affecting the urinary system in varying capacities, growing geriatric population base where age itself plays a major role in disease etiology and technical innovation in product development such as the manufacture of drug-coated balloon catheters aimed at drug delivery at the site of action among other factors are expected to drive the balloon catheters market during the forecast period from 2023-2028.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TMINI Miniature Robotic System by THINK Surgical Received FDA 510(k) Clearance On May 30, 2023, THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TMINI&#x2122; Miniature Robotic System. A wireless robotic handpiece that is part of the TMINI system [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":23282,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":8,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20749,19053,19842,17110,17109,20748,20752,20722,20487,19325,19126,20751,20750,20031,20030,2731,20747,19028,20746],"industry":[],"therapeutic_areas":[17242,17241,17245],"class_list":["post-23279","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anika-therapeutics","tag-balloon-catheters","tag-balloon-catheters-market","tag-cardiac-monitoring-devices","tag-cardiac-monitoring-devices-market","tag-cepheid","tag-emvision","tag-eosolutions","tag-heartbeam","tag-in-vitro-diagnostics-market","tag-in-vitro-diagnostics-2","tag-knee-reconstruction-devices","tag-knee-reconstruction-devices-market","tag-neurology-devices","tag-neurology-devices-market","tag-samsung","tag-surgical-robotic-system-market","tag-surgical-robotic-systems","tag-think-surgical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-musculoskeletal","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Cepheid, Anika, EMVision, Eosolutions<\/title>\n<meta name=\"description\" content=\"THINK Surgical\u2019s TMINI Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast Phase III Study; Eosolutions\u2019s Dr. Banner Balloon\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Cepheid, Anika, EMVision, Eosolutions\" \/>\n<meta property=\"og:description\" content=\"THINK Surgical\u2019s TMINI Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast Phase III Study; Eosolutions\u2019s Dr. Banner Balloon\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T13:13:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T05:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Cepheid, Anika, EMVision, Eosolutions","description":"THINK Surgical\u2019s TMINI Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast Phase III Study; Eosolutions\u2019s Dr. Banner Balloon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Cepheid, Anika, EMVision, Eosolutions","og_description":"THINK Surgical\u2019s TMINI Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast Phase III Study; Eosolutions\u2019s Dr. Banner Balloon","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-06-01T13:13:10+00:00","article_modified_time":"2023-06-14T05:33:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision","name":"MedTech News | Cepheid, Anika, EMVision, Eosolutions","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision.png","datePublished":"2023-06-01T13:13:10+00:00","dateModified":"2023-06-14T05:33:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"THINK Surgical\u2019s TMINI Robotic System; Cepheid\u2019s Xpert NPM1 Mutation Test; Anika\u2019s Hyalofast Phase III Study; Eosolutions\u2019s Dr. Banner Balloon","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cepheid-anika-emvision#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision.png","width":772,"height":482,"caption":"MedTech News for Cepheid, Anika, EMVision"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/01113114\/MedTech-News-for-Cepheid-Anika-EMVision-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anika Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Balloon Catheters<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Balloon Catheters Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiac monitoring devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiac monitoring devices market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cepheid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EMVision<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eosolutions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HeartBeam<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">In Vitro Diagnostics Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">In-Vitro Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Knee Reconstruction Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Knee Reconstruction Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurology Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurology Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SAMSUNG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">THINK Surgical<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Anika Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Balloon Catheters<\/span>","<span class=\"advgb-post-tax-term\">Balloon Catheters Market<\/span>","<span class=\"advgb-post-tax-term\">Cardiac monitoring devices<\/span>","<span class=\"advgb-post-tax-term\">Cardiac monitoring devices market<\/span>","<span class=\"advgb-post-tax-term\">Cepheid<\/span>","<span class=\"advgb-post-tax-term\">EMVision<\/span>","<span class=\"advgb-post-tax-term\">Eosolutions<\/span>","<span class=\"advgb-post-tax-term\">HeartBeam<\/span>","<span class=\"advgb-post-tax-term\">In Vitro Diagnostics Market<\/span>","<span class=\"advgb-post-tax-term\">In-Vitro Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Knee Reconstruction Devices<\/span>","<span class=\"advgb-post-tax-term\">Knee Reconstruction Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Neurology Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurology Devices Market<\/span>","<span class=\"advgb-post-tax-term\">SAMSUNG<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/span>","<span class=\"advgb-post-tax-term\">THINK Surgical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 1, 2023","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jun 1, 2023 6:43 pm","modified":"Updated on Jun 14, 2023 11:03 am"},"featured_img_caption":"MedTech News for Cepheid, Anika, EMVision","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23279"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23279\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23282"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23279"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23279"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}